Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Substituted pyrazolopyrimidine scaffold derivatives: MerckRecent Research Landscape

Fluctuating drug plasma levels lead to reduced efficacy and increased side effects in neurological treatments. These innovations control the pharmacokinetic profile through specialized delivery matrices to ensure therapeutic stability.

What technical problems is Merck addressing in Substituted pyrazolopyrimidine scaffold derivatives?

Impaired dopaminergic signaling regulation

(4)evidences

Short half-lives and rapid clearance of PDE10 inhibitors lead to frequent dosing requirements. Sustained release delivery overcomes these pharmacokinetic limitations to maintain stable plasma concentrations.

Insufficient phosphodiesterase enzyme inhibition

(2)evidences

Inadequate regulation of intracellular signaling pathways due to overactive phosphodiesterase enzymes. Restoring signaling balance improves cognitive and cardiovascular function.